Stevens Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Stevens Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-8,919	Closed	-$382K	–	4
2019 Q4	$382K	Buy	+8,919	New	+$388K	0.04%	398
2018 Q4	–	Sell	-57,727	Closed	-$1.2M	–	672
2018 Q3	$1.2M	Sell	57,727 -5,169	-8%	-$81.3K	0.04%	399
2018 Q2	$960K	Buy	62,896 +1,577	+3%	+$28.1K	0.03%	438
2018 Q1	$1.38M	Buy	61,319 +2,802	+5%	+$77.6K	0.05%	357
2017 Q4	$1.76M	Buy	+58,517	New	+$1.87M	0.07%	318
2017 Q1	–	Sell	-36,171	Closed	-$1.04M	–	844
2016 Q4	$1.04M	Sell	36,171 -20,978	-37%	-$555K	0.04%	424
2016 Q3	$1.82M	Buy	+57,149	New	+$1.94M	0.08%	300
2014 Q3	–	Sell	-11,199	Closed	-$253K	–	966
2014 Q2	$253K	Buy	+11,199	New	+$234K	0.01%	865

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Stevens Capital Management's ACAD Position: Q1 2020 in Review

Stevens Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2020, closing a stake of 8,919 shares — an estimated $382K sold.

Stevens Capital Management first reported a position in ACAD in Q2 2014 and held it in 8 quarters. The position peaked at $1.82M in Q3 2016. 245 funds tracked by Wall St. Rank hold ACAD as of Q1 2020.

Stevens Capital Management reported no remaining Acadia Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Stevens Capital Management sold 8,919 Acadia Pharmaceuticals shares in Q1 2020, an estimated $382K.
Stevens Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2014 and held it in 8 quarters.
Stevens Capital Management's Acadia Pharmaceuticals position peaked at $1.82M in Q3 2016.
245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2020.

Based on Stevens Capital Management's 13F filing for Q1 2020, filed 21 Apr 2020.